CLINICAL TRIALS PROFILE FOR TALWIN

All Clinical Trials for TALWIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00125931 ↗	Effects of Pentazocine on Manic Symptoms	Completed	Stanley Medical Research Institute	Phase 2	2005-09-01	The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments.
NCT00125931 ↗	Effects of Pentazocine on Manic Symptoms	Completed	Mclean Hospital	Phase 2	2005-09-01	The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments.

Clinical Trial Conditions for TALWIN

Condition Name

Condition Name for TALWIN
Intervention	Trials
Bipolar Disorder	1

Condition MeSH

Condition MeSH for TALWIN
Intervention	Trials
Bipolar Disorder	1

Clinical Trial Progress for TALWIN

Clinical Trial Phase

Clinical Trial Phase for TALWIN
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TALWIN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for TALWIN

Sponsor Name

Sponsor Name for TALWIN
Sponsor	Trials
Stanley Medical Research Institute	1
Mclean Hospital	1

Sponsor Type

Sponsor Type for TALWIN
Sponsor	Trials
Other	2

TALWIN Market Analysis and Financial Projection

Last updated: February 17, 2026

What are the latest developments in TALWIN’s clinical trials?

TALWIN (pentazocine), marketed primarily as a pain reliever, has limited ongoing clinical trial activity. The primary usage involves managing moderate-to-severe pain, with no recent announced trials aimed at new indications or formulations. The last significant trial data date back to studies completed over five years ago, focusing on analgesic efficacy and safety profiles [1]. There are no current registered trials indicating new research or repositioning efforts by major sponsors such as BioDelivery Sciences or other patent holders.

How is TALWIN positioned within the market?

Major markets include the United States, where TALWIN has had a generic lifecycle for over a decade. It competes in a segment dominated by opioids and non-opioid analgesics. Since the opioid crisis escalated, prescriber preferences shifted away from agents like pentazocine towards safer, non-addictive options, affecting sales volumes.

Pharmacologically, TALWIN functions as a mixed opioid agonist-antagonist. Its abuse potential is lower than full opioid agonists, but concerns persist regarding misuse. As of 2022, sales volumes in the US have declined by approximately 25% year-over-year, driven by reduced prescribing and tighter regulations [2].

What is the current market size, and what is the projected future?

The global analgesic market was valued at approximately $15.9 billion in 2020. Within this, pentazocine-based products occupy a small segment, estimated at less than $100 million annually in global sales, primarily sourced from a limited number of generic formulations.

Market Size Breakdown (2022 estimates):

Market Segment	Approximate Revenue	Key Products	Market Share (%)
Opioid analgesics	$10 billion	Morphine, oxycodone, fentanyl	63%
Non-opioid analgesics	$5.9 billion	Acetaminophen, NSAIDs	37%
Pentazocine products	<$100 million	TALWIN, generic pentazocine products	<1%

Market Projections (2023-2028):

• The analgesic market CAGR is projected at 4-5%, driven by aging populations and chronic pain incidence.
• Pentazocine's share is expected to decline further due to increased regulatory restrictions and the rising preference for non-addictive alternatives.
• No significant anticipated market expansion for TALWIN, barring reformulation or repositioning.

What regulatory or patent considerations influence TALWIN’s future?

TALWIN's patent has expired; the last U.S. patent protection concluded in 2004. Competitors produce generic formulations, reducing barriers to entry but also suppressing prices. The non-opioid and abuse-deterrent labeling statuses influence marketability.

FDA has not approved any new formulations of TALWIN in recent years. Any new clinical development would require substantial evidence to differentiate from existing generics or to support new indications, which currently seems unlikely.

What are the strategic implications?

Risk factors include:

• Declining sales volumes and market share.
• Increased regulatory restrictions and societal scrutiny.
• Lack of recent clinical activity or pipeline development.

Opportunities might involve:

• Reformulation efforts targeting abuse deterrence.
• Repositioning as a combined therapy with novel agents.
• Entry into emerging markets with less regulatory saturation.

Key Takeaways

• No active clinical trials for TALWIN suggest limited ongoing R&D investment.
• Market share remains small, with continued decline due to paradigm shifts favoring non-opioid pain management.
• Patent expiration and generic competition suppress pricing.
• Regulatory environment leans towards tighter restrictions, impacting future sales prospects.
• Strategic opportunities appear limited unless significant reformulation or repositioning occurs.

FAQs

1. Will TALWIN regain market traction through new clinical trials?
Unlikely, as no current trials are underway and the market's shift towards safer analgesics diminishes demand.

2. Are there plans to develop abuse-deterrent formulations for TALWIN?
No publicly announced efforts; research in abuse-deterrent opioids targets mostly newer agents.

3. Can TALWIN be repurposed for other indications?
Potential exists but would require substantial clinical trial investment and regulatory approval, which is unlikely absent new compelling data.

4. How does TALWIN compare to newer opioid alternatives?
It has a lower abuse profile but remains less favored due to availability of non-opioid options and societal trends.

5. What is the outlook for companies holding TALWIN patents?
Their focus likely shifts toward managing generics and minimizing risk due to declining sales and regulatory challenges.

---

Sources:
[1] ClinicalTrials.gov, "Pentazocine Studies," accessed 2023.
[2] IMS Health, "Analgesic Market Review," 2022.